We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Adriaan Voors

Adriaan A. Voors MD, PhD

Professor of Cardiology, Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands

Adriaan Voors is Professor of Cardiology and specializes in heart failure. Since July 2003, Professor Voors is working as a Cardiologist in the University Medical Centre Groningen, The Netherlands. In 2007, he became Established Clinical Investigator of the Netherlands Heart Foundation, and in May 2010, he became Professor of Cardiology at the University Medical Center Groningen. Currently, Professor Voors is Director of the Heart Failure Clinic of the Department of Cardiology of the University Medical Center Groningen. Professor Voors supervised 40 PhD students, mainly on heart failure related topics. He is an editorial board member of the European Journal of Heart Failure, Clinical Research in Cardiology, Cardiovascular Drugs and Therapy, the Journal of Cardiovascular Medicine, and Heart Failure Reviews. He is/was involved as  principal investigator/executive/steering committee member of 49 clinical trials on novel therapies in acute and chronic heart failure. Prof. Voors was a member of the 2012 ESC Heart Failure Guidelines Committee, and was the co-chair of the 2016 ESC Heart Failure Guidelines.

Disclosures

Dr. Voors serves as a consultant for AstraZeneca and Boehringer Ingelheim, has received research support from Boehringer Ingelheim, is the principal investigator of the EMPULSE trial with empagliflozin, and was an executive committee member of SOLOIST-WHF with sotagliflozin (Sanofi/Lexicon Pharmaceuticals).